EGFR and head and neck squamous cell carcinoma: EGFR inhibition in HNSCC by cetuximab is known to promote antibody-dependent cellular cytotoxicity by recruiting natural killer (NK) cells and also elevates the numbers of certain T cell populations namely PD-1 and TIM-3 positive CD8+ T cells [138].